Opaxio
Generic name: paclitaxel poliglumex
Treatment for: Non Small Cell Lung Cancer, Ovarian Cancer, Glioblastoma Multiforme, Head and Neck Cancer
Opaxio Combined with Alimta Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
Encouraging progression-free survival in investigator sponsored trial results published at 13th World Conference on Lung Cancer
SEATTLE, August 03, 2009 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. The study demonstrated that in patients with advanced non-small cell lung cancer (NSCLC), the combination of OPAXIO (paclitaxel poliglumex) and Alimta(R) (pemetrexed) was well tolerated and resulted in median progression-free survival of 3.3 months.
The study, led by Dr. J. R. Rigas, enrolled twelve patients, six to each of two dose levels. Patients were treated in 21-day cycles, with cohort one receiving 135 mg/m2 of paclitaxel poliglumex and 500 mg/m2 of pemetrexed, and cohort two receiving 175 mg/m2 of paclitaxel poliglumex and 500 mg/m2 of pemetrexed. None of the patients in cohort one had an initial dose-limiting toxicity (IDLT) with two cycles of therapy. There was one IDLT of infection with neutropenia in cohort two. Aside from grade 3 fatigue in two patients, there were no grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was delivered in each cohort.
The best response was stable disease in nine patients. Two patients remain without evidence of disease progression, and six patients were alive at time of data presentation. Median progression free survival was 3.3 months.
OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit .
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: deramian@ctiseattle.com Investors Contact: Ed Bell T: 206.282.7100 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: invest@ctiseattle.com Medical Information Contact: T: 800.715.0944 E: info@askarm.com
SOURCE Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, Cell, +1-206-854-1200,, Investors, Ed Bell, +1-206-282-7100, Lindsey JeschLogan, +1-206-272-4347, fax, +1-206-272-4434, , all ofCell Therapeutics, Inc., Medical Information, +1-800-715-0944, deramian@ctiseattle.com invest@ctiseattle.com info@askarm.com
Ticker Symbol: (NASDAQ-NMS:CTIC)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: August 2009
Related articles
- Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer - January 28, 2014
- High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO Phase II Study Reported in American Journal of Clinical Oncology - February 24, 2011
- Paclitaxel Poliglumex (OPAXIO) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer - November 22, 2010
- OPAXIO Phase II Study Results Confirm High Rate of Complete Response with Low Rate of Side Effects in Patients with Advanced Esophageal Cancer - June 7, 2010
- OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer - October 3, 2009
- Paclitaxel Poliglumex (OPAXIO Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer - June 5, 2009
- Paclitaxel Poliglumex (Opaxio)/Capecitabine Regimen Well Toleratedand Active in Metastatic Breast Cancer - June 3, 2008
- Lung Cancer Alliance Hails FDA Decision to Expedite Review of Xyotax Treatment for Lung Cancer - April 17, 2007
- CTI and FDA Agree on NDA Filing Strategy for Xyotax - June 1, 2006
- CTI Plans to Submit Marketing Applications for Xyotax - August 24, 2005
Opaxio (paclitaxel poliglumex) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.